Maj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth, Martin Schønemann-Lund, Gitte-Bettina Nyvang, Charlotte Aaquist Haslund, Anja Oer Knudsen, Anne Krejbjerg Motavaf, Susanne Malander, Maarit Anttila, Gabriel Lindahl, Johanna Mäenpää, Maria Dimoula, Theresa L Werner, Trine Zeeberg Iversen, Sakari Hietanen, Lars Fokdal, Hanna Dahlstrand, Line Bjørge, Michael J Birrer, Mansoor R Mirza, Maria Rossing
{"title":"Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.","authors":"Maj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth, Martin Schønemann-Lund, Gitte-Bettina Nyvang, Charlotte Aaquist Haslund, Anja Oer Knudsen, Anne Krejbjerg Motavaf, Susanne Malander, Maarit Anttila, Gabriel Lindahl, Johanna Mäenpää, Maria Dimoula, Theresa L Werner, Trine Zeeberg Iversen, Sakari Hietanen, Lars Fokdal, Hanna Dahlstrand, Line Bjørge, Michael J Birrer, Mansoor R Mirza, Maria Rossing","doi":"10.1158/2767-9764.CRC-24-0294","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"3190-3200"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670052/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Significance: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
